Virometix, a Schlieren, Switzerland-based biotechnology company, completed a CHF 7.5m Series B equity financing round.
Backers included existing and new private investors.
Led by Anna Sumeray, Chief Executive Officer, Virometix is a biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases.
The new funds, which will be added to the previous seed and Series A financings of CHF 10.3m, bringing the total capital raised to date by Virometix to CHF 17.8m, will be used to complete the phase 1 clinical trial of its lead asset V-306 in RSV (respiratory syncytial virus), advance pre-clinical development of its vaccine candidates against SARS-CoV-2, progress other research collaborations and strengthen the team.
In conjunction with the funding, Axel Polack and Sumeray have been elected to the Board of Directors of Virometix.
Dr Polack holds a Medical Doctorate degree from the Albert-Ludwigs-Universität Freiburg and Habilitation (postdoctoral lecture qualification) in Virology from the Ludwig-Maximilians-Universität Munich. He has experience as a board member and a biotech investor and was a partner at TVM Capital from 2000– 2014.
Sumeray has more than has over 25 years of experience in the life sciences sector with a combination of strategic consultancy, hands-on P&L leadership and deal transaction experience in big pharmaceutical and small biotechnology companies, globally, across Europe and within individual countries.
FinSMEs
20/07/2020